Aseptic process validation of [18F]Sodium Fluoride radiopharmaceutical in-house production
-
Published:2023-01
Issue:1
Volume:68
Page:37-42
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Atanasova Lazareva Marija1, Kolevska Katerina1, Chochevska Maja1, Velickovska Maja1, Jolevski Filip1, Ugrinska Ana1, Janevik-Ivanovska Emilija2
Affiliation:
1. University Institute of Positron Emission Tomography, Skopje, Bledski dogovor 10, 1000 Skopje, North Macedonia 2. Faculty of Medical Sciences, Goce Delcev University, Krste Misirkov 10-A, 2000 Stip, North Macedonia
Abstract
Sodium fluoride ([18F]NaF) is a PET radiopharmaceutical for vizualization of the skeletal system and microcalcification. In the originally designed in-house method, [18F]NaF is recovered in aqueous solution after cyclotron irradiation, sterilized by passage through a 0.22 µm sterile filter and dispensed under aseptic conditions. To ensure the microbiological safety of drugs produced under aseptic conditions, validation of aseptic procedures is always recommended. This is essential for radiopharmaceuticals because most of them are released for administration before any sterility test can be completed due to their radioactive nature.
This study reports the validation of the aseptic process applied to the internal production of [18F]NaF carried out in two phases: testing the number of viable microorganisms in radiopharmaceutical product prior to sterilization and process simulation studies (media fill tests). We found that all samples were sterile and the endotoxin concentration was well below the maximum acceptable level reported in the Ph Eur. monograph on [18F]NaF. The results confirmed that the entire production process of [18F]NaF can be carried out under strictly aseptic conditions following the validated procedures preserving the sterility of the final product.
Keywords: [18F]NaF, radiopharmaceutical, validation, aseptic process
Publisher
Macedonian Pharmaceutical Association
Reference20 articles.
1. Aerts, J., Ballinger, J.R., Behe, M., Decristoforo, C., Elsinga, P.H., Faivre-Chauvet, A., Mindt, T. L., Kolenc Peitl, P., Todde, S.C., Koziorowski, J. & European Association of Nuclear Medicine, 2014. Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. J. Label Compd. Radiopharm. 57, 615– 620. Available at: https://doi.org/10.1002/jlcr.3227 2. Ahuja, K., Sotoudeh, H., Galgano, S.J., Singh, R., Gupta, N., Gaddamanugu, S., Choudhary, G., 2020. 18F-Sodium Fluoride PET: History, Technical Feasibility, Mechanism of Action, Normal Biodistribution, and Diagnostic Performance in Bone Metastasis Detection Compared with Other Imaging Modalities. Journal of Nuclear Medicine Technology 48(1), 9–16. Available at: https://doi.org/10.2967/jnmt.119.234336 3. Becker, K., Heilmann, C., Peters G., 2014. Coagulase-negative staphylococci. Clin. Microbiol. Rev. 27(4), 870-926. Available at: https://doi.org/10.1128/CMR.00109-13 4. Blau, M., Ganatra, R., Bender, M.A., 1972. 18 F-fluoride for bone imaging. Semin. Nucl. Med. 2(1), 31-37. Available at: https://doi.org/10.1016/S0001-2998(72)80005-9 5. CDER, 2012. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/media-fills-validation-aseptic-preparations-positron-emission-tomography
|
|